Keapstone Therapeutics (AgeTech UK) Biomed

Developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).
Technology: AgeTech Companies
Industry: UK AgeTech 2020
Headquarters: United Kingdom
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership